DrugPatentWatch Database Preview
Abaloparatide - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for abaloparatide and what is the scope of patent protection?
Abaloparatide
is the generic ingredient in one branded drug marketed by Radius Health Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Abaloparatide has thirty-eight patent family members in twenty-five countries.
One supplier is listed for this compound.
Summary for abaloparatide
| International Patents: | 38 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 5 |
| Clinical Trials: | 13 |
| Patent Applications: | 35 |
| Drug Prices: | Drug price trends for abaloparatide |
| DailyMed Link: | abaloparatide at DailyMed |
Recent Clinical Trials for abaloparatide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daniel Horwitz | Phase 4 |
| Jacqueline Kernaghan | Phase 4 |
| Crozer-Keystone Health System | Phase 4 |
Pharmacology for abaloparatide
| Drug Class | Parathyroid Hormone-Related Peptide Analog |
US Patents and Regulatory Information for abaloparatide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radius Health Inc | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Radius Health Inc | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Radius Health Inc | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Radius Health Inc | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for abaloparatide
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 20091545 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008063279 | Start Trial |
| Israel | 197926 | Start Trial |
| Norway | 344885 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
